Thr224

Site Information
ERLIDAKtGLPVKTD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 23086606

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 ) , mutation of modification site ( 1 )
Disease tissue studied:	leukemia ( 2 ) , chronic myelogenous leukemia ( 2 ) , fibrosarcoma of soft tissue ( 1 )
Relevant cell line - cell type - tissue:	Calu-1 (squamous) ( 1 ) , HT1080 (fibroblast) ( 1 ) , K562 (erythroid) ( 2 )

References
1	Wang D, et al. (2023) Identification and characterization of the CDK1-BMAL1-UHRF1 pathway driving tumor progression. iScience 26, 106544 37123229 Curated Info
2	Moritz A (2011) CST Curation Set: 11304; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info

References

Wang D, et al. (2023) Identification and characterization of the CDK1-BMAL1-UHRF1 pathway driving tumor progression. iScience 26, 106544
37123229 Curated Info

Moritz A (2011) CST Curation Set: 11304; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info